Compromised dYdX npm and PyPI packages delivered wallet-stealing malware and a RAT via poisoned updates in a software supply chain attack.

A number of stocks fell in the afternoon session after markets pulled back as reports surfaced that Chinese customs authorities blocked Nvidia's H200 AI chips, effectively halting their entry despite ...

Earlier this week, Veeva Systems’ board approved a share repurchase program authorizing the company to buy back up to US$2.00 billion of its Class A common stock over the next two years, while also ...

Veeva Systems shares were 7% higher, at $235.89, after the company said its board of directors approved a share-repurchase program with authorization to buy up to $2 billion of its shares. Under the ...

The latest announcement is out from Veeva Systems ( (VEEV)). On January 5, 2026, Veeva Systems announced that its board had authorized the company’s first-ever share repurchase program, allowing the ...

For the three and nine months ended October 31, 2025 and 2024, management used an estimated annual effective non-GAAP tax rate of 21.0%. View original content to ...

The Details: Veeva reported quarterly earnings of $2.04 per share, which beat the analyst estimate of $1.95. Quarterly revenue of $811.2 million beat the Street estimate of $792.82 million.

The latest announcement is out from Veeva Systems ( (VEEV)). On November 17, 2025, Veeva Systems Inc. announced that Kristine Diamond, the Chief Accounting Officer, will resign from her position ...

Veeva Systems Inc. (NYSE:VEEV) is one of the best digital health stocks to buy now. On November 4, 2025, Veeva announced that its Veeva Basics solution has been adopted by “more than 100 biotechs” to ...

The Investment Committee give you their top stocks to watch for the second half. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your ...

The yearslong legal kerfuffle between IQVIA and Veeva Systems has come to a close, with the former adversaries setting aside their differences to launch a series of clinical and commercial ...